November 17th – A vaccine against COVID-19 developed in China safely produces antibodies to the virus in 92% of those who receive it, according to a study published by The Lancet Infections on Tuesday.
Nonetheless, antibody levels in participants who received an injection called Corona Vac were lower than those found in patients who recovered after infection, the researchers said.
The trials were not designed to evaluate the efficacy of the vaccine, but they said their studies were ongoing.
“Our findings show that Corona Vac can elicit a rapid antibody response within 4 weeks of immunization by administering the vaccine twice at 14-day intervals,” said study co-author Fengcai Zhu. Stated in a statement.
“We believe this will make the vaccine suitable for emergency use during a pandemic,” said Zhu, a researcher at the Centers for Disease Control and Prevention in Jiangsu Province, Nanjing, China.
The findings are up-to-date with the hope that a viable vaccine against COVID-19 will be available in the short term.
Recently, both Pfizer and Moderna have published positive preliminary results for their respective vaccines. Over 120 potential vaccines have been evaluated and 48 are in clinical trials.
CoronaVac is a chemically inactivated whole-virus vaccine based on the coronavirus strain that causes COVID-19 and was originally isolated from Chinese patients.
This Phase 1/2 is the first phase of the evaluation process, a two-part clinical trial, in which the health of more than 700 people between the ages of 18 and 59 in China between April 16 and May 5 Corona Vac was administered to the volunteers.
Participants had no history of COVID-19 infection, had never traveled to areas with a high incidence of the disease, and had no signs of fever when vaccinated, the researchers said.
In both parts of the study, participants were divided into two groups and received one of the two vaccination schedules. Inject twice every 14 days or twice every 28 days.
Within each of the two groups, participants were randomly assigned to receive either a low dose of vaccine (3 micrograms) or a high dose of 6 mcg.
The antibody response, a protein produced by the immune system to fight the virus, can be triggered within 28 days of initial immunization by giving two low-dose vaccines at 14-day intervals. The data is shown.
In Phase 1 of the study, the vaccine evoked an immune response in 46% of participants. This more than doubled in the second phase to just over 92%.
The vaccines used in the second phase of the study were produced using a different manufacturing process that might have made it possible to generate a stronger immune response, the researchers said.
Participants at all dosing schedules and levels reported similar side effects, with injection site pain being the most common.
Most of the reported side effects were mild and participants recovered within 48 hours.
According to study co-author Dr. Gang Zeng, CoronaVac can be stored in a standard refrigerator at 36-46 degrees Fahrenheit. It is “typical of many existing vaccines, including influenza” and can be stored for up to 3 years. China-based Sinovac Biotech, which manufactures vaccines.
China’s COVID-19 vaccine is said to be promising in early clinical trials
Source link China’s COVID-19 vaccine is said to be promising in early clinical trials